PADI2 and secondary progressive multiple sclerosis: The presence of anti-PAD2 antibodies in subsets of people with RRMS and SPMS and association with a less severe disease in MS suggests that these antibodies may define a mechanistically distinct group of patients in which PAD2 plays a pathogenic role.